Jun 2017

Axxam coordinates European research project on chronic pain for innovative medicines

Milan (Italy) – June 15th, 2017 – Axxam is proud to announce its participation to the NGN-PET project, that will provide a translational platform of rodent and human neuropathic pain models for the identification and validation of new targets and biomarkers, and suitable for the discovery of new drugs. The project investigates neuron-glia interactions for the identification of novel therapeutic approaches, and for the development of innovative drug screening systems including hiPSC systems.
The IMI2 project was launched on April the 1st  and is coordinated by Axxam; the project Leader is ESTEVE supported by Grünenthal GmbH as project Co-Leader.
For more information please open the Press Release from the NGN-PET Consortium.

Open PDF document

Feb 2017

Axxam and Fulcrum Therapeutics Initiate a Partnership for the Provision of Drug Discovery Services for Genetic Diseases

February 1st, 2017 - Axxam SpA (Milan/Italy), an innovative Partner Research Organization (iPRO) and leading provider of discovery services has entered into an agreement with Fulcrum Therapeutics Inc., a U.S.-based biotech founded in July 2016 by Third Rock Ventures. Fulcrum Therapeutics is focused on discovering and developing small molecule therapies to unlock gene control and the collaboration will utilize Axxam’s world-leading screening platform to identify novel targets for regulating gene expression. The programme will initially focus on genetic diseases where no effective treatment options currently exist.

Open PDF Document

Jan 2017

Axxam SpA is a member of the PHAGO Consortium

Milan (Italy) - January, 11th 2017 - Axxam is proud to announce its participation to the PHAGO project, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD). Axxam will contribute its expertise for the development of high-throughput screening systems suitable for the discovery of modulators of the TREM2/CD33 pathway. For more information please open the Press Release from the Phago Consortium.

Open PDF document